507 related articles for article (PubMed ID: 29157685)
81. Inhibition of the MET Kinase Activity and Cell Growth in MET-Addicted Cancer Cells by Bi-Paratopic Linking.
Andres F; Iamele L; Meyer T; Stüber JC; Kast F; Gherardi E; Niemann HH; Plückthun A
J Mol Biol; 2019 May; 431(10):2020-2039. PubMed ID: 30930049
[TBL] [Abstract][Full Text] [Related]
82. Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.
Finisguerra V; Prenen H; Mazzone M
Oncogene; 2016 Oct; 35(42):5457-5467. PubMed ID: 26996670
[TBL] [Abstract][Full Text] [Related]
83. Discovery and development of ASK1 inhibitors.
Brys R; Gibson K; Poljak T; Van Der Plas S; Amantini D
Prog Med Chem; 2020; 59():101-179. PubMed ID: 32362327
[TBL] [Abstract][Full Text] [Related]
84. Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).
Ugolini A; Kenigsberg M; Rak A; Vallée F; Houtmann J; Lowinski M; Capdevila C; Khider J; Albert E; Martinet N; Nemecek C; Grapinet S; Bacqué E; Roesner M; Delaisi C; Calvet L; Bonche F; Semiond D; Egile C; Goulaouic H; Schio L
J Med Chem; 2016 Aug; 59(15):7066-74. PubMed ID: 27355974
[TBL] [Abstract][Full Text] [Related]
85. Design, Synthesis and Biological Evaluation of 6,7-Disubstituted-4-phenoxyquinoline Derivatives Bearing Pyridazinone Moiety as c-Met Inhibitors.
Liu X; Kou J; Xiao Z; Tian F; Hu J; Zheng P; Zhu W
Molecules; 2018 Jun; 23(7):. PubMed ID: 29949931
[TBL] [Abstract][Full Text] [Related]
86. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.
You WK; McDonald DM
BMB Rep; 2008 Dec; 41(12):833-9. PubMed ID: 19123972
[TBL] [Abstract][Full Text] [Related]
87. Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library.
Mortazavi M; Raufi E; Damghani T; Khoshneviszadeh M; Edraki N; Eskandari M; Giovannetti E; Peters GJ; Pirhadi S; Firuzi O
Eur J Pharmacol; 2023 Jan; 938():175395. PubMed ID: 36410418
[TBL] [Abstract][Full Text] [Related]
88. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.
Guessous F; Zhang Y; diPierro C; Marcinkiewicz L; Sarkaria J; Schiff D; Buchanan S; Abounader R
Anticancer Agents Med Chem; 2010 Jan; 10(1):28-35. PubMed ID: 20015006
[TBL] [Abstract][Full Text] [Related]
89. Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors.
Verkhivker GM
Curr Med Chem; 2017; 24(42):4838-4872. PubMed ID: 27719654
[TBL] [Abstract][Full Text] [Related]
90. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies.
Jiang WG; Martin TA; Parr C; Davies G; Matsumoto K; Nakamura T
Crit Rev Oncol Hematol; 2005 Jan; 53(1):35-69. PubMed ID: 15607934
[TBL] [Abstract][Full Text] [Related]
91. MET: a promising anticancer therapeutic target.
Peters S; Adjei AA
Nat Rev Clin Oncol; 2012 May; 9(6):314-26. PubMed ID: 22566105
[TBL] [Abstract][Full Text] [Related]
92. Discovery of a selective c-MET inhibitor with a novel binding mode.
Collie GW; Barlind L; Bazzaz S; Börjesson U; Dale IL; Disch JS; Habeshian S; Jetson R; Khurana P; Madin A; Michaelides IN; Peng L; Snijder A; Stubbs CJ
Bioorg Med Chem Lett; 2022 Nov; 75():128948. PubMed ID: 35987508
[TBL] [Abstract][Full Text] [Related]
93. The clinical and functional significance of c-Met in breast cancer: a review.
Ho-Yen CM; Jones JL; Kermorgant S
Breast Cancer Res; 2015 Apr; 17(1):52. PubMed ID: 25887320
[TBL] [Abstract][Full Text] [Related]
94. Development for anticancer therapy: small-molecule inhibitors targeting protein kinase B.
Chen SF; Chen JZ
Mini Rev Med Chem; 2013 Jul; 13(9):1272-94. PubMed ID: 22512570
[TBL] [Abstract][Full Text] [Related]
95. Advances in MET tyrosine kinase inhibitors in gastric cancer.
Zhang Y; Shen L; Peng Z
Cancer Biol Med; 2024 May; 21(6):484-98. PubMed ID: 38727001
[TBL] [Abstract][Full Text] [Related]
96. Recent Patents on the Development of c-Met Kinase Inhibitors.
Xu X; Yao L
Recent Pat Anticancer Drug Discov; 2020; 15(3):228-238. PubMed ID: 32603284
[TBL] [Abstract][Full Text] [Related]
97. c-Met inhibitors with different binding modes: two is better than one.
Dussault I; Bellon SF
Cell Cycle; 2008 May; 7(9):1157-60. PubMed ID: 18418040
[TBL] [Abstract][Full Text] [Related]
98. Targeting RSK: an overview of small molecule inhibitors.
Nguyen TL
Anticancer Agents Med Chem; 2008 Oct; 8(7):710-6. PubMed ID: 18855572
[TBL] [Abstract][Full Text] [Related]
99. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.
Bradley CA; Salto-Tellez M; Laurent-Puig P; Bardelli A; Rolfo C; Tabernero J; Khawaja HA; Lawler M; Johnston PG; Van Schaeybroeck S;
Nat Rev Clin Oncol; 2017 Sep; 14(9):562-576. PubMed ID: 28374784
[TBL] [Abstract][Full Text] [Related]
100. Targeting the c-MET signaling pathway for cancer therapy.
Liu X; Yao W; Newton RC; Scherle PA
Expert Opin Investig Drugs; 2008 Jul; 17(7):997-1011. PubMed ID: 18549337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
